Imunon

IMNN

Penny Stock

$1.07arrow_drop_down6.14%-$0.07

Penny Stock

IMNN

$1.07

arrow_drop_down6.14%-$0.07

Penny Stock

Performance History

There's no data available for key stats

There's no data available for ratios/profitability stats

Score Breakdown

There's no data available for score breakdown

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About Imunon (IMNN)

Imunon, Inc. (IMNN) is a biotechnology company focused on developing innovative immunotherapies for the treatment of various diseases. The company's stock price history has shown fluctuations over the years, reflecting the dynamic nature of the biotech industry. Investors interested in IMNN can find the latest stock quote on reputable financial websites or through their preferred brokerage platforms.

For those seeking comprehensive information about Imunon, Inc., it is advisable to explore reputable sources for stock news and analysis. These sources often provide insights into the latest developments, milestones, and financial performance of the company. By staying informed about IMNN, investors can make more educated decisions regarding their investment strategies. IMNN's market cap provides an indication of the company's overall value in the stock market. This figure is calculated by multiplying the current share price by the total number of outstanding shares.

Websitecall_made

Sector: Healthcare
Industry: Biotechnology
CEO: Dr. Corinne M. Le Goff M.B.A., Pharm.D.
Headquarters: Lawrenceville
Employees: 31
Exchange: NASDAQ

Keep an eye on Imunon

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is Imunon's (IMNN) price per share?

The current price per share for Imunon (IMNN) is $1.07. The stock has seen a price change of -$0.07 recently, indicating a -6.14% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for Imunon (IMNN)?

For Imunon (IMNN), the 52-week high is $3.65, which is 241.12% from the current price. The 52-week low is $0.48, the current price is 122.92% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is Imunon (IMNN) a growth stock?

Imunon (IMNN) has shown an average price growth of 0.41% over the past three years. It has received a score of 30 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Imunon as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is Imunon (IMNN) stock price performance year to date (YTD)?

As of the latest data, Imunon (IMNN) has a year-to-date price change of 57.33%. Over the past month, the stock has experienced a price change of -11.57%. Over the last three months, the change has been 0.94%. Over the past six months, the figure is 32.75%.

help

Is Imunon (IMNN) a profitable company?

Imunon (IMNN) has a net income of -$19.51M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 0% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. Operating income is noted at -$21.03M. Furthermore, the EBITDA is -$19.62M.

help

What is the market capitalization of Imunon (IMNN)?

Imunon (IMNN) has a market capitalization of $16.42M. The average daily trading volume is 270.33K, indicating the stock's liquidity and investor engagement.

News

IMUNON Announces Database Lock for Phase 2 OVATION 2 Study with IMNN-001 in Advanced Ovarian Cancer

PRESS RELEASES

6/24/2024

IMUNON Announces Database Lock for Phase 2 OVATION 2 Study with IMNN-001 in Advanced Ovarian Cancer

First Participants Vaccinated in IMUNON’s IMNN-101 Phase 1 Clinical Trial

PRESS RELEASES

6/5/2024

First Participants Vaccinated in IMUNON’s IMNN-101 Phase 1 Clinical Trial

Abstract on Phase 2 Study with IMUNON’s IMNN-001 Plus Bevacizumab Accepted for Presentation at the American Society of Clinical Oncology Annual Meeting

PRESS RELEASES

5/15/2024

Abstract on Phase 2 Study with IMUNON’s IMNN-001 Plus Bevacizumab Accepted for Presentation at the American Society of Clinical Oncology Annual Meeting